Heart failure & cardiomyopathiesSecondary analysis
Effects of Empagliflozin on Uric Acid Levels During Acute Heart Failure Recompensation: A Sub-Analysis of the EMPAG-HF Trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure)
- Secondary analysis of the EMPAG-HF randomised trial
- single-centre
- prospective
- double-blind
- placebo-controlled
Authors' conclusion
Addition of empagliflozin to standard diuretic therapy may prevent the rise in SUA during decongestion in patients with ADHF and thus may prevent negative effects of hyperuricaemia including the occurrence of acute gout episodes.
Study context
- Population
- Patients with acute decompensated HF (acute decompensated heart failure (ADHF)), randomised within 12 h of admission, irrespective of LVEF or DM
- Participants
- 60 patients
- Comparison
- Empagliflozin vs placebo added to standard medical treatment
Primary result
As reported in the abstract
Serum uric acid (SUA) · 3, 4 and 5 days
- Serum uric acid (SUA) increased with placebo during diuretic therapy but decreased with empagliflozin
- SUA significantly lower with empagliflozin vs placebo at 3, 4 and 5 days
- SUA reduction with empagliflozin associated with enhanced renal uric acid excretion
Original publication
Effects of Empagliflozin on Uric Acid Levels During Acute Heart Failure Recompensation: A Sub-Analysis of the EMPAG-HF Trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure). Eur J Heart Fail. Published 9 July 2025. doi:10.1002/ejhf.3723
Summarised from the published abstract; every number is checked against it